This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.
This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.Session 3-CT-MPD17. SGLT2 Inhibitors-Understanding the Benefits and the Risks-And the Beat Goes On. ADA Scientific Sessions, New Orleans, LA. June 11, 2016.Â
Understanding SGLT2 Inhibitors.
Safety and Efficacy of Dapagliflozin (DAPA) in Combination with Potassium (K)-sparing Agents
effects of DAPA 10 mg vs. placebo in patients treated with K-sparing agents
DAPA and potassium-sparing agents study results
Impact of Exposure to SGLT2 Inhibitors on Incidence of Diabetic Ketoacidosis among Danish Type 2 Diabetes Patients
SGLT2 inhibitors and DKA incidence
DKA hazard ratios
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Trial assessed changes in HbA1c, body weight, systolic BP, and albuminuria with placebo or DAPA 10 mg
